Survjit Cheeta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6563489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Trends in Mortality From Novel Psychoactive Substances as "Legal Highsâ€; Gender Differences in Manner of Death and Implications for Risk Differences for Women. Frontiers in Psychiatry, 2022, 13, 890840.	2.6	4
2	Seeing sadness: Comorbid effects of loneliness and depression on emotional face processing. Brain and Behavior, 2021, 11, e02189.	2.2	7
3	Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people. BMJ Open, 2018, 8, e021109.	1.9	17
4	Neuroticism related differences in working memory tasks. PLoS ONE, 2018, 13, e0208248.	2.5	16
5	Gambling disorder and suicidality within the UK: an analysis investigating mental health and gambling severity as risk factors to suicidality. International Gambling Studies, 2017, 17, 51-64.	2.1	9
6	National survey of alcohol treatment agencies in England: Characteristics of clients. Journal of Substance Use, 2012, 17, 389-398.	0.7	0
7	The perceived challenges facing alcohol treatment services in England: A qualitative study of service providers. Journal of Substance Use, 2011, 16, 38-49.	0.7	2
8	Low identification of alcohol use disorders in general practice in England. Addiction, 2008, 103, 766-773.	3.3	60
9	Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. British Journal of Psychiatry, 2004, 184, 41-47.	2.8	261
10	Corticotropin releasing factor antagonist, α-helical CRF9–41, reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology, 2003, 167, 251-256.	3.1	36
11	Cause and manner of death in drug-related fatality: an analysis of drug-related deaths recorded by coroners in England and Wales in 2000. Drug and Alcohol Dependence, 2003, 72, 67-74.	3.2	44
12	Nicotinic–serotonergic interactions in brain and behaviour. Pharmacology Biochemistry and Behavior, 2002, 71, 795-805.	2.9	142
13	Conditioned anxiety to nicotine. Psychopharmacology, 2002, 164, 309-317.	3.1	22
14	Tolerance to midazolam's anxiolytic effects after short-term nicotine treatment. Neuropharmacology, 2001, 40, 710-716.	4.1	17
15	The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology, 2001, 155, 78-85.	3.1	106
16	Social isolation modifies nicotine's effects in animal tests of anxiety. British Journal of Pharmacology, 2001, 132, 1389-1395.	5.4	68
17	Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacology Biochemistry and Behavior, 2001, 68, 319-325.	2.9	86
18	Different treatment regimens and the development of tolerance to nicotine's anxiogenic effects. Pharmacology Biochemistry and Behavior, 2001, 68, 769-776.	2.9	29

SURVJIT CHEETA

#	Article	IF	CITATIONS
19	Antagonism of the anxiolytic effect of nicotine in the dorsal raphé nucleus by dihydro-β-erythroidine. Pharmacology Biochemistry and Behavior, 2001, 70, 491-496.	2.9	42
20	Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action. Brain Research, 2001, 888, 311-313.	2.2	42
21	Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Research, 2001, 894, 95-100.	2.2	20
22	In Adolescence, Female Rats Are More Sensitive to the Anxiolytic Effect of Nicotine Than Are Male Rats. Neuropsychopharmacology, 2001, 25, 601-607.	5.4	77
23	The role of 5-HT1Areceptors in mediating the anxiogenic effects of nicotine following lateral septal administration. European Journal of Neuroscience, 2000, 12, 3797-3802.	2.6	46
24	The Role of the Dorsal Hippocampal Serotonergic and Cholinergic Systems in the Modulation of Anxiety. Pharmacology Biochemistry and Behavior, 2000, 66, 65-72.	2.9	225
25	Neurobiological mechanisms by which nicotine mediates different types of anxiety. European Journal of Pharmacology, 2000, 393, 231-236.	3.5	98
26	Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 1053-1067.	4.8	75
27	Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1A and not by muscarinic M1 receptors. Neuropharmacology, 2000, 39, 300-307.	4.1	56
28	"Depression" increases "craving" for sweet rewards in animal and human models of depression and craving. Psychopharmacology, 1998, 136, 272-283.	3.1	162
29	Changes in sleep architecture following chronic mild stress. Biological Psychiatry, 1997, 41, 419-427.	1.3	156
30	Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology, 1994, 115, 454-462.	3.1	119
31	Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology, 1994, 116, 523-528.	3.1	46